Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

ZYMAR OPHTHALMIC SOLUTION 0.3% [SIN12612P]

Active ingredients: ZYMAR OPHTHALMIC SOLUTION 0.3%

View product's general information
Last updated 24 April 2026

Product Info

ZYMAR OPHTHALMIC SOLUTION 0.3%

[SIN12612P]

Product information

Active Ingredient and Strength

GATIFLOXACIN - 3 MG/ML

Dosage Form

SOLUTION

Manufacturer and Country

ALLERGAN SALES LLC - UNITED STATES

Registration Number

SIN12612P

Licence Holder

ABBVIE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

S01AX21

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

INDICATIONS AND USAGE

ZYMAR® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:

Table caption

Aerobic Gram-Positive Bacteria:

Cornyebacterium propinquum*

Streptococcus mitis*

Staphylococcus aureus

Streptococcus pneumoniae

Staphylococcus epidermidis

Aerobic Gram-Negative Bacteria:

Haemophilus influenzae

* Efficacy for this organism was studied in fewer than 10 infections.

Dosing

DOSAGE AND ADMINISTRATION

The recommended dosage regimen for the treatment of bacterial conjunctivitis is:

Days 1 and 2: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times daily.

Days 3 through 7: Instill one drop up to four times daily while awake.

Contraindications

CONTRAINDICATIONS

ZYMAR® solution is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication.